Top 5 Drug Type | Count |
---|---|
Small molecule drug | 18 |
Monoclonal antibody | 1 |
Target |
Mechanism KRAS G12C inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Dec 2022 |
Target |
Mechanism MUT stimulants [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Nov 2021 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 May 2017 |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date30 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Adagrasib ( KRAS G12C ) | KRAS G12C mutant Colorectal Cancer More | Approved |
Nivolumab ( PD-1 ) | Advanced Lung Non-Small Cell Squamous Carcinoma More | Phase 3 |
Sitravatinib ( AXL x RET x Tie-2 x VEGFR1 x VEGFR2 x VEGFR3 x c-Met ) | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma More | Phase 3 |
TNO-155 ( SHP2 ) | Advanced cancer More | Phase 2 Clinical |
MRTX-0902 ( SOS1 ) | Colorectal Cancer More | Phase 2 Clinical |